SCHEMBL3093141

SCHEMBL3093141

CCC(CC)(C(N)=O)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LARS1 Q9P2J5 1/20 0.53
LMNA P02545 3/20 0.49
F2 P00734 3/20 0.49
PRSS1 P07477 3/20 0.49
PRSS2 P07478 3/20 0.49
PRSS3 P35030 3/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
RAPGEF3 O95398 1/20 0.48
NLRP3 Q96P20 1/20 0.47
ALDH1A1 P00352 6/20 0.47
KDM4E B2RXH2 2/20 0.47
KMT2A Q03164 2/20 0.47
GAA P10253 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
CTSS P25774 1/20 0.44
SLC1A3 P43003 1/20 0.44
SLC1A2 P43004 1/20 0.44
SLC1A1 P43005 1/20 0.44
HPGD P15428 1/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3085657 0.99 LARS1 (0.52) LARS1LMNAF2PRSS1PRSS2
SCHEMBL3470158 0.90 LARS1 (0.51) LARS1LMNAF2PRSS1PRSS2
SCHEMBL3097522 0.87 RAPGEF3 (0.57) LARS1RAPGEF3ALDH1A1KDM4EKMT2A
SCHEMBL3470357 0.87 LARS1 (0.48) LARS1LMNAF2PRSS1PRSS2
SCHEMBL3469824 0.83 F2 (0.56) LARS1LMNAF2PRSS1PRSS2
SCHEMBL3092148 0.81 MCL1 (0.53) BCL2L1MCL1
SCHEMBL3088414 0.80 ALDH1A1 (0.49) LMNAF2PRSS1PRSS2PRSS3
SCHEMBL3469570 0.80 LARS1 (0.56) LARS1LMNAF2PRSS1PRSS2
SCHEMBL17943496 0.79 L3MBTL1 (0.58) LARS1LMNAF2PRSS1PRSS2
SCHEMBL3103556 0.79 ALDH1A1 (0.50) LMNAF2PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LARS1 1976/4885LMNA 3803/4885F2 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.